Success Metrics

Completion Rate
0%(0/1)
Active Trials
4(80%)
Terminated
1(20%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
1
20%
Ph phase_1
1
20%
Ph phase_4
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Active, not recruiting4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)

Trials by Status

terminated120%
active_not_recruiting480%

Recent Activity

4 active trials
Showing 5 of 5
active_not_recruitingphase_2

Telitacicept for PGNMID: A Single-Arm Study

NCT07111338
active_not_recruitingphase_3

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

NCT07098897
active_not_recruitingphase_4

Immune Cell Subsets in SLE Patients Treated with Telitacicept

NCT06677801
active_not_recruitingphase_1

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

NCT06656962
terminatedphase_2

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

NCT04905212

Clinical Trials (5)

Showing 5 of 5 trials
NCT07111338Phase 2

Telitacicept for PGNMID: A Single-Arm Study

Active Not Recruiting
NCT07098897Phase 3

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active Not Recruiting
NCT06677801Phase 4

Immune Cell Subsets in SLE Patients Treated with Telitacicept

Active Not Recruiting
NCT06656962Phase 1

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Active Not Recruiting
NCT04905212Phase 2

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5